Novo's CagriSema Hits 25% Weight Loss, But Is It Enough?

Novo Nordisk announced promising results from a Phase 3 trial of its next-generation obesity drug, CagriSema. The drug combines semaglutide (the active ingredient in Wegovy and Ozempic) with cagrilintide, a compound that mimics the appetite-regulating hormone amylin. In the trial, women taking CagriSema achieved an average weight loss of nearly 25% after 68 weeks, compared to just 3% for those on a placebo.

The analysis focused on 2,309 women, with a subgroup of 1,902 women with overweight or obesity due to menopause showing weight loss between 23% and nearly 27%, depending on menopausal stage. These results are significantly better than Wegovy's roughly 15% weight loss in its pivotal trial and are comparable to Eli Lilly's Zepbound, which achieved about 21% in its pivotal trial and up to 26% in a head-to-head study against CagriSema.

Investors reacted cautiously, sending Novo Nordisk shares up about 2.4% on the news. The muted response reflects concerns that CagriSema, while effective, may not be enough to regain market share from Eli Lilly, whose Zepbound has overtaken Wegovy in U.S. weekly prescriptions since early 2025.

Novo Nordisk's stock has struggled amid intense competition and other challenges, making these results a rare piece of positive news. However, the company's pipeline extends beyond obesity, with programs targeting cardiovascular disease, liver disease, and endocrine disorders, which could offer longer-term growth opportunities.

The obesity drug market is massive and growing, and Novo Nordisk's ability to compete effectively is crucial for its stock price. CagriSema's efficacy, while strong, appears roughly on par with Zepbound rather than clearly superior. In the head-to-head Redefine 4 trial, Zepbound's active ingredient tirzepatide showed either similar or slightly higher efficacy, reaching nearly 26% weight loss at the maximum dose. This suggests CagriSema may not be a 'Zepbound-killer' but rather a competitive alternative.

Eli Lilly has established a commanding lead in the U.S. market, with Zepbound prescriptions surpassing Wegovy's at the start of 2025. For Novo Nordisk to turn around its beaten-down stock, it needs a clear competitive advantage, which CagriSema alone may not provide. The cautious investor reaction underscores this skepticism.

However, Novo Nordisk's broader pipeline could hold the key to a turnaround. The company is developing treatments for cardiovascular disease, blood and endocrine disorders, liver disease, and other ailments. If one of these programs yields a best-in-class or first-in-class drug, it could materially improve the company's fortunes. For now, CagriSema's success is a step forward but not a game-changer.

Investors should watch for further data on CagriSema, including overall trial results and regulatory submissions, as well as updates on Novo's other pipeline assets. The competitive dynamics with Eli Lilly will remain a key driver of both stocks.